# A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

> **NCT01342679** · PHASE2 · COMPLETED · sponsor: **Kanto CML Study Group** · enrollment: 21 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT01342679
- **Lead sponsor:** Kanto CML Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-03
- **Final completion:** 2014-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342679, "A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01342679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*